About Dr. Basu

The research interests of Ananda Basu, MBBS, M.D., include:

  • Development of an effective artificial pancreas system for people with type 1 diabetes using the closed-loop system of insulin delivery and glucose sensing (primary interest). Along with co-principal investigator Yogish C. Kudva, MBBS, Dr. Basu has been successful in securing funding from the National Institutes of Health for an artificial pancreas program. To supplement federal funding, Dr. Basu and Dr. Kudva are in the process of applying to other organizations and seeking benefactor support. They have also recently accepted an invitation from the Juvenile Diabetes Research Foundation to join its Artificial Pancreas Project Consortium.
  • Exploring the role of the central nervous system and carotid bodies on glucose homeostasis in humans. Dr. Basu is involved in developing precise and novel techniques with pinpoint spatial accuracy to detect central neuronal changes in vivo in the human brain in response to enteral nutrients and changes in circulating insulin and glucose concentrations. He is also part of a federal grant (principal investigators on the grant are Michael J. Joyner, M.D., and Rita Basu, M.D.) that is exploring the role of carotid bodies on glucose counter-regulation in humans with translational relevance to hypoglycemia unawareness in those with type 1 diabetes mellitus.
  • Link between diabetes and vascular disease. The primary cause of death in people with diabetes is macrovascular disease. Therapeutic interventions directed toward controlling hyperglycemia have so far not proved beneficial toward lowering the risks of these vascular events. Dr. Basu is interested in determining the pathophysiological link between diabetes and vascular disease, which could lead to rational therapy to prevent these devastating events. To achieve these goals, Dr. Basu is working on two initial projects:
    • Investigating the effects of glucagon-like peptide 1 and glucagon-like peptide 1 analogs on vascular and myocardial function in people with and without diabetes
    • Identifying circulating cellular and noncellular mediators that contribute to accelerated atherosclerosis in type 2 diabetes